Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2047-9158
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease ; volume:5 ; number:1 ; day:29 ; month:11 ; year:2016 ; pages:1-6 ; date:12.2016
Translational neurodegeneration ; 5, Heft 1 (29.11.2016), 1-6, 12.2016
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Zhang, Bei
- Beteiligte Personen und Organisationen
-
Li, Qiongqiong
Chu, Xingkun
Sun, Suya
Chen, Shengdi
SpringerLink (Online service)
- DOI
-
10.1186/s40035-016-0068-y
- URN
-
urn:nbn:de:1111-201701146389
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Bei
- Li, Qiongqiong
- Chu, Xingkun
- Sun, Suya
- Chen, Shengdi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease
Influence of different types of amyloid β pathologies on tau pathology in Alzheimer´s disease in different APP-TAU double transgenic mouse models
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Propagation of Tau pathology in Alzheimer disease
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease
Influence of different types of amyloid β pathologies on tau pathology in Alzheimer´s disease in different APP-TAU double transgenic mouse models
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Propagation of Tau pathology in Alzheimer disease
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice
Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer’s disease models
Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease
Influence of different types of amyloid β pathologies on tau pathology in Alzheimer´s disease in different APP-TAU double transgenic mouse models
Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer’s disease
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Propagation of Tau pathology in Alzheimer disease